![]() |
市场调查报告书
商品编码
1750766
Frost Radar:RWE 生命科学解决方案 2025Frost Radar: Life Sciences Real-World Evidence Solutions, 2025 |
基准化分析系统激励主要企业-创新推动新的交易流程和成长管道
不断发展的IT格局在生命科学领域发挥了变革性作用,使得对RWE解决方案的依赖成为可能。随着竞争日益激烈以及对决策精准度的需求不断增长,製药公司、医疗保健提供者和科技公司逐渐意识到,RWD技术在促进研究、优化临床试验和改善患者疗效方面至关重要。
该平台和实行技术製药和生物技术公司在整个产品生命週期中利用监管级 RWE,包括早期研究、临床开发、发布计划、基于价值的合约、纵向病患监测和患者活化。
生命科学 RWE 解决方案产业较为分散,约有 120 家供应商在资料聚合、整合、互通性和预测分析等领域开展业务,为製药公司提供高品质的见解。
Frost & Sullivan 筛选并分析了超过 45 家 RWE 解决方案供应商,透过深入分析这些供应商的成长潜力及其推动行业前瞻性创新的能力,最终列出了 16 家主要企业。 Frost Radar™ 主要对资料整合、管理、分析和洞察领域的公司进行基准测试,并在资料收集领域拥有强大的影响力。其他领域的解决方案和实行技术对评估产生了积极影响。
在对供应商进行基准测试时,Frost & Sullivan 会根据关键标准评估每个供应商的产品组合,包括数据整合、数据品质、高级分析、可扩展性、即时存取、云端支援、协作、监管专业知识、以患者为中心的方法、创新、敏捷性和成本效益,从而使生命科学公司能够与最适合其不断发展的定制需求的供应商合作。
Frost & Sullivan 会分析同一产业内大量的公司。根据领导力和其他特征,筛选出需要进一步分析的公司,并根据 10 项成长和创新标准进行基准测试,以揭示其在 Frost Radar™ 上的排名。 Frost Radar™ 上每家公司的竞争概况都会进行展示,探讨其优势以及最契合这些优势的商业机会。
A Benchmarking System to Spark Companies to Action - Innovation That Fuels New Deal Flow and Growth Pipelines
The evolving IT landscape has played a transformative role in the field of life sciences, enabling a reliance on real-world evidence (RWE) solutions. With growing competition and the demand for precision in decision-making, pharmaceutical companies, healthcare providers, and technology organizations have realized the need for real-world data (RWD) to boost research while optimizing clinical trials and improving patient outcomes.
The platforms and enabling technologies help pharma/biotech companies harness regulatory-grade RWE across the product lifecycle, including early-stage research, clinical development, launch planning, value-based contracting, long-term patient monitoring, and patient activation.
The life sciences RWE solutions industry is fragmented, with about 120 vendors operating in this space across areas including data aggregation, integration, interoperability, and predictive analytics to provide pharmaceutical companies with high-quality insights.
Frost & Sullivan screened and analyzed more than 45 RWE solution vendors and short-listed the leading 16 companies based on a detailed analysis of their corporate growth potential and ability to drive visionary innovation in this industry. This Frost Radar™ benchmarks companies primarily in data integration, management, analytics, and insights with a strong play in the data collection segment. Solutions in other segments and enabling technologies had a positive impact on their ratings.
When benchmarking vendors, Frost & Sullivan evaluated their portfolios across key criteria, such as data integration, data quality, advanced analytics, scalability, real-time access, cloud support, collaboration, regulatory expertise, patient-centric approaches, innovation, agility, and cost-effectiveness to ensure that life sciences companies partner with the best vendor for their evolving and customized needs.
Frost & Sullivan analyzes numerous companies in an industry. Those selected for further analysis based on their leadership or other distinctions are benchmarked across 10 Growth and Innovation criteria to reveal their position on the Frost Radar™. The publication presents competitive profiles of each company on the Frost Radar™ considering their strengths and the opportunities that best fit those strengths.